argenx (ARGX) Q1 2025 earnings summary

Executive summary

• Achieved $790 million in global product net sales in Q1 2025, up 99% year-over-year and 7% sequentially from Q4 2024, driven by strong demand for VYVGART in gMG and CIDP and the launch of a pre-filled syringe for self-injection in the US and Germany.

• Maintained leadership in the MG market, with VYVGART achieving the fastest market share growth among branded biologics and strong commercial momentum in both gMG and CIDP indications.

• Continued robust pipeline progress, with 10 registrational and 10 proof-of-concept studies ongoing, multiple readouts expected in 2025–2027, and four new pipeline candidates nominated.

• Vision 2030 remains on track, aiming to reach 50,000 patients across 10 labeled indications and advance five phase III assets.

• Ended Q1 2025 with $3.6 billion in cash, cash equivalents, and current financial assets, supporting ongoing investment in innovation and pipeline development.

Financial highlights

• Q1 2025 total operating income: $807 million, with $790 million from product net sales (99% growth YoY); operating profit: $139 million, reversing a $93 million loss in Q1 2024.

• Regional net sales: $681M U.S., $32M Japan, $57M rest of world, $20M China (Zai Lab); US net sales grew 96% YoY, Japan up 82%, RoW up 89%, China up 757%.

• Net profit for Q1 2025 was $169 million, compared to a net loss of $62 million in Q1 2024; diluted EPS was $2.58, basic EPS $2.78.

• Gross margin: 90% (cost of sales $81 million); operating expenses: $668 million (2% QoQ increase).

• Cash balance at quarter end: $3.6 billion, up $238 million from Q4 2024, driven by operational cash flow.

Outlook and guidance

• Confident in continued consistent growth for the remainder of 2025, supported by new product launches, expanding indications, and global expansion.

• Guidance for total R&D and SG&A for the year remains at $2.5 billion.

• Multiple pipeline readouts and regulatory decisions expected through 2027, including phase III seronegative gMG and phase II studies in lupus nephritis, delayed graft function, and CMS.